Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma

[1]  P. Hammond,et al.  SURG-03. LAYER-BY-LAYER CORE-SHELL NANOPARTICLES FOR THE DELIVERY OF HDAC INHIBITORS TO THE CENTRAL NERVOUS SYSTEM , 2023, Neuro-Oncology.

[2]  Matthew D. Dun,et al.  The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies , 2022, Neuro-oncology.

[3]  Aubry K. Miller,et al.  Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target , 2022, Nature Chemical Biology.

[4]  Trevor J Pugh,et al.  Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency , 2022, Nature medicine.

[5]  Matthew D. Dun,et al.  Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies , 2021, Oncogene.

[6]  E. Konofagou,et al.  Focused Ultrasound-Mediated Blood-Brain Barrier Opening Enhances Panobinostat Efficacy in a Murine Diffuse Intrinsic Pontine Glioma Model. , 2021, International journal of radiation oncology, biology, physics.

[7]  J. Ojemann,et al.  Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis , 2021, Nature Medicine.

[8]  J. Olson,et al.  A Protocol for the Generation of Treatment-naïve Biopsy-derived Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma Models , 2020, Journal of experimental neurology.

[9]  Emily J. Girard,et al.  Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models. , 2020, Neuro-oncology.

[10]  Patrick J. Paddison,et al.  A simple and highly efficient method for multi‐allelic CRISPR‐Cas9 editing in primary cell cultures , 2020, Cancer reports.

[11]  J. Olson,et al.  Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children’s Hospital experience , 2020, Journal of Neuro-Oncology.

[12]  Raymond Y Huang,et al.  Mechanisms and therapeutic implications of hypermutation in gliomas , 2020, Nature.

[13]  Zhangguo Chen,et al.  HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma , 2020, Protein & Cell.

[14]  Jonathan S. Packer,et al.  Massively multiplex chemical transcriptomics at single-cell resolution , 2019, Science.

[15]  Allison P. Heath,et al.  Pediatric high-grade glioma resources from the Children’s Brain Tumor Tissue Consortium , 2019, bioRxiv.

[16]  Pierre Autin,et al.  Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors , 2019, Cancers.

[17]  Vernell S. Williamson,et al.  Lynch syndrome–associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome , 2019, Cold Spring Harbor molecular case studies.

[18]  Yulun Huang,et al.  Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells , 2019, Journal of Cancer.

[19]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[20]  M. Abedalthagafi.  Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies , 2018, Oncotarget.

[21]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.

[22]  S. Albrecht,et al.  Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency , 2018, Pediatric blood & cancer.

[23]  S. Ramkissoon,et al.  Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency. , 2018, The oncologist.

[24]  S. Larson,et al.  Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial , 2018 .

[25]  Michael C. Heinold,et al.  The landscape of genomic alterations across childhood cancers , 2018, Nature.

[26]  K. T. Householder,et al.  pH driven precipitation of quisinostat onto PLA-PEG nanoparticles enables treatment of intracranial glioblastoma , 2018, Colloids and surfaces. B, Biointerfaces.

[27]  V. Ramaswamy,et al.  Integrating RNA sequencing into neuro‐oncology practice , 2017, Translational research : the journal of laboratory and clinical medicine.

[28]  Kun Mu,et al.  Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma , 2017, Cancer cell.

[29]  James Suh,et al.  Comprehensive Genomic Profiling of 282 Pediatric Low‐ and High‐Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures , 2017, The oncologist.

[30]  Meng Li,et al.  Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. , 2017, Cancer cell.

[31]  D. Merico,et al.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Monje,et al.  Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. , 2016, Neuro-oncology.

[33]  R. Pili,et al.  Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. , 2016, Epigenomics.

[34]  Nicholas J. Wang,et al.  Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma , 2015, Nature Medicine.

[35]  Roland Arnold,et al.  Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers , 2015, Nature Genetics.

[36]  Chris Jones,et al.  Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma , 2014, Nature Reviews Cancer.

[37]  C. Hawkins,et al.  High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan , 2014, International journal of cancer.

[38]  Stephen Yip,et al.  Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma , 2014, Nature Genetics.

[39]  Amar Gajjar,et al.  The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.

[40]  David T. W. Jones,et al.  K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.

[41]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[42]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[43]  T. Zhou,et al.  Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. , 2011, Neuro-oncology.

[44]  P. A. Futreal,et al.  Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment , 2007, Clinical Cancer Research.

[45]  Tracy T Batchelor,et al.  A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. , 2006, Cancer research.

[46]  Ping-Hui Tseng,et al.  Histone Acetylation-independent Effect of Histone Deacetylase Inhibitors on Akt through the Reshuffling of Protein Phosphatase 1 Complexes* , 2005, Journal of Biological Chemistry.

[47]  M. Monje,et al.  Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials , 2019, Current Treatment Options in Neurology.

[48]  Michelle Monje,et al.  Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets , 2016, Current neuropharmacology.